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Background: Coronary heart disease is a leading cause of death in the world and therapy to reduce injury is still
needed. The uncoupling of glycolysis and glucose oxidation induces lactate accumulation during myocardial
ischemia/reperfusion (I/R) injury. Cell death occurs and finally leads to myocardial infarction. Caffeic acid, one of the
major phenolic constituents in nature, acts as an antioxidant. Pyrrolidinyl caffeamide (PLCA), a new derivative of
caffeic acid, was synthesized by our team. We aimed to investigate the effect of PLCA on hypoxia/reoxygenation
(H/R) in neonatal rat ventricular myocytes (NRVM) and on myocardial I/R in rats.
Results: Cardiomyocytes were isolated and subjected to 6 h hypoxia followed by 18 h reperfusion. PLCA (0.1 to
3 μM) and metformin (30 μM) were added before hypoxia was initiated. PLCA at 1 μM and metformin at 30 μM
exerted similar effects on the improvement of cell viability and the alleviation of cell apoptosis in NRVM after H/R.
PLCA promoted p-AMPK, p-AKT, and GLUT4 upregulation to induce a cardioprotective effect in both cell and animal
model. The accumulation of cardiac lactate was attenuated by PLCA during myocardial I/R, and infarct size was
smaller in rats treated with PLCA (1 mg/kg) than in those treated with caffeic acid (1 mg/kg).
Conclusions: AMPK and AKT are synergistically activated by PLCA, which lead facilities glucose utilization, thereby
attenuating lactate accumulation and cell death. The cardioprotective dose of PLCA was lower than those of
metformin and caffeic acid. We provide a new insight into this potential drug for the treatment of myocardial I/R
injury.
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Coronary heart disease is a leading cause of death in the
world [1]. With ischemia in coronary heart disease, im-
pairment of the oxygen supply and metabolic disorder
both occur [2]. Without oxygen, anaerobic glycolysis
occurs accompanied by lactate accumulation, leading to
intracellular acidosis [2]. The PH value fall results in
elevating of NADH/NAD+ ratio and further inhibiting
ATP production [3,4]. The re-establishing of blood flow
to an ischemic zone is called reperfusion [1]. A high
intracellular calcium concentration and the production
excess reactive oxygen species inhibit the mitochondrial
electron transport chain causing cell damage [5]. Cell* Correspondence: mingja@ntu.edu.tw
1Institute of Pharmacology, College of Medicine, National Taiwan University,
No.1, Sec.1, Jen-Ai Road, Taipei 100, Taiwan
Full list of author information is available at the end of the article
© 2015 Lee et al.; licensee BioMed Central. Th
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.apoptosis occurs, such as by activation of caspase-3
activity, and finally leads to myocardial infarction [1].
Reducing the size of myocardial infarct is the determin-
ing factor of clinical outcomes in acute coronary artery
disease [6,7]. A therapeutic drug that targets ischemia
reperfusion (I/R) injury is needed and has yet to be
developed.
AMPK, an important energy sensor and metabolic
regulator, is modulated by the ratio of [ATP]/[AMP] ×
[ADP] [8]. This is important in the setting of myocardial
ischemia reperfusion (I/R) due to high energy demands
and low energy reserves. During hypoxia, the decline of
ATP induces AMPK activation [9]. AMPK phosphoryl-
ation enhances glycolysis by two mechanisms. In the first,
glucose uptake is increased by stimulation of GLUT4
expression [10]. In the second, 6-phosphofructo-2-kinase
activity is enhanced [11]. AMPK also increases fatty acidis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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carboxylase, along with the decreasing concentration of
malonyl-CoA, an inhibitor of fatty acid transport into
mitochondria [12]. Metformin, an anti-hyperglycemic
agent that activates AMPK [13], is known to have cardi-
oprotective effects against I/R injury [14].
Energy production is also controlled by AKT, which is
a serine/threonine protein kinase [15]. PI3K/AKT signal-
ing is involved in the insulin pathway, which plays a key
role on glucose metabolism [16]. AKT phosphorylation
increases glucose utilization by increasing glycolysis and
glucose oxidation [16-18]. AKT enhances the expression
and translocation of GLUT4 through the phosphoryl-
ation of AS160 to promotes glucose uptake [16,19], and
increases glycolysis by phosphorylating hexokinase [17].
AKT inhibits fatty acid oxidation through down regula-
tion of PPARα/PCG-1-dependent transcription [18] and
promote glucose oxidation via Randle cycle mechanism
[20]. Facilitation of glucose utilization contributes to
the protective effect of AKT signaling to reduce infarct
size and improve myocardial function in a heart sub-
jected to I/R [15].
Caffeic acid, one of the major phenolic constituents in
nature, acts as an antioxidant [21]. Previous research has
revealed that caffeic acid reduces oxidative stress and
exerts a protective effect on the cardiovascular system
[22,23]. In addition, caffeic acid has been reported to
activate AMPK [24]. Our new synthetic derivative of
caffeic acid is pyrrolidinyl caffeamide (PLCA) from the
laboratory of YH Kao’s (Figure 1). The effect of PLCA
on the cardiovascular system is unknown; therefore,
we aimed to assess the protective effects of PLCA on
hypoxia/reoxygenation (H/R) induced in neonatal ven-
tricular myocytes and myocardial I/R injury in rats.
Methods
Isolated neonatal rat ventricle myocytes (NRVM)
The investigation conformed to the Guide for the Care
and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85–23,
revised 1996). NRVM was isolated from 2-day-oldFigure 1 Structure of pyrrolidinyl caffeamide (PLCA).Sprague–Dawley rats. Hearts were excised and digested
with enzyme mixtures containing pancreatin (Sigma-
Aldrich, St. Louis, MO, USA) and collagenase (GIBCO,
Grand Island, NY, USA) dissolved in Ca2+/Mg2+-free
Hank’s balanced saline solution. Cell suspensions were
pre-plated for 90 min by seeding on an uncoated plate
to select the cardiac fibroblasts. The unattached cells were
NRVM, which were cultured with Eagle’s minimal essen-
tial medium supplemented with 10% fetal calf serum and
antibiotics (100 μg/ml penicillin and 100 μg/ml strepto-
mycin) at 37°C under a 5% CO2 − 95% air atmosphere for
the first day. On the second day, a confluent monolayer of
spontaneously beating NRVMs was formed. All experi-
ments were performed with contractile myocyte-rich
monolayers with 90-95% confluence. Serum was deprived
for 12 h before experiments initiated.
Experimental model of H/R in NRVM
NRVM were exposed to 6 h hypoxia (5% CO2, 1.8% O2,
93.2% N2) followed by 12 h reoxygenation. The H/R
model mimics I/R injury in clinical conditions. In the
normoxia condition, 2.2 g/L NaHCO3 was added to the
medium to adjust PH to 7.4. In the hypoxia condition,
sodium lactate (8 μM) was added to the medium to
induce stress, and the PH value of the medium was
adjusted to 6.8 by adding 0.57 g/L NaHCO3, according
to the Henderson-Hasselbalch equation: PH = 6.1 + log
[52 × (mg/ml NaHCO3/%CO2) -1] [25]. PLCA (0.1, 0.3, 1,
and 3 μM) and metformin (30 μM) were added to the
medium before hypoxia was initiated. Compound C
(15 μM) and LY294002 (15 μM) were added to evaluate
the mechanisms of PLCA.
Detection of cell viability
Cell viability was determined by MTT assay as describe
prevsiouly [26]. Cells were treated with MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide) at
0.5 mg/ml. The purple formazan crystals were dissolved in
DMSO. Solutions were then loaded in a 96 well plate, and
determined on an automated microplate spectrophotom-
eter at 570 nm. Each condition tested was performed in
triplicate in each experiment.
Detection of cell death
Cell death was detected with a detection kit (BD,
USA). Cells were incubated with Annexin V-FITC and
propidium iodide (PI). The reagent was incubated at
room temperature for 15 min in the dark, and detected
by fluorescence microscopy. In this procedure, green
fluorescence indicates early apoptosis (Annexin V-
FITC positive and PI negative) and orange indicates
late apoptosis or death (annexin V-FITC positive and
PI positive).
Lee et al. Journal of Biomedical Science  (2015) 22:18 Page 3 of 9Experimental model of myocardial I/R injury in vivo
Eight-week-old male Sprague–Dawley rats (BioLASCO
Taiwan, Co., Ltd, Taipei, Taiwan) were used. Animals
were maintained under a 12-h light/dark cycle at a con-
trolled temperature (21 ± 2°C) with free access to food
and tap water. Rats were anesthetized and subjected to
1 h coronary artery occlusion, followed by 2 h reperfu-
sion as described previously [27]. PLCA (1 mg/kg) or
caffeic acid (1 mg/ kg) was administered by intraperito-
neal injection 15 min before I/R started. At the end of I/
R, the hearts were harvested and the coronary artery
was ligated again and perfused with 1% evan blue to dis-
tinguish between the normoxia and risk area. Each heart
was then sliced horizontally, incubated in 1% triphenyl-
tetrazolium chloride (Sigma, St. Louis, MO, USA) for
30 min at 37°C, and then placed in 10% formaldehyde.
The infarct area appeared white.Protein extraction from cardiac tissue
NRVMs or heart tissue were obtained at the end-point
of the experiment. Proteins were homogenized in RIPA
buffer (Tris–HCl 50 mM, NaCl 150 mM, EGTA 1 mM,
EDTA 1 mM, NP-40 1%, sodium deoxycholate 1%)
containing cocktail protease and phosphatase inhibitor
(Sigma, St. Louis, MO, USA). The supernatant of hom-
ogenate was collected after centrifugation (800 × g,
10 min at 4°C). Protein concentrations were determined
by BCA protein assay kit (Thermo Fisher Scientific Inc.,
Rockford, IL, USA).Determination of cardiac lactate level
Heart protein was collected at the end of I/R experi-
ment. Cardiac lactate level was measured by ELISA kit
(Biovision, USA).Western blot analysis
The protein expression in NRVM or rat heart were ana-
lyzed by western blotting with method described previ-
ously [26]. Briefly, equal amounts of protein samples
were separated by SDS-PAGE and transferred to poly-
vinylidene difluoride membranes (Perkin-Elmer Life
Sciences, Boston, MA, USA). The membranes were
blocked in 5% fat-free milk dissolved in TBST (Tris/
phosphate/saline/Tween) and incubated with primary
antibody to p-AMPK, p-AKT, caspase-3 (Cell Signalling,
Beverly, MA, USA), GLUT4 (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), and β-actin (Sigma-Aldrich).Figure 2 Effect of PLCA and metformin on cell viability in
NRVM after H/R stress. Cell viability was measured after NRVM
subjected to 6 h hypoxia, and followed by 12 h reoxygenation. PLCA
(0.1, 0.3, 1, and 3 μM) and metformin (30 μM) were treated before
hypoxia initiated. (n = 8) *P < 0.05 vs. control, #P < 0.05 vs. H/R +
vehicle. Met = metformin.Statistical analysis
All values are presented as means ± SE. The results were
analyzed using ANOVA followed by Bonferroni’s post
hoc tests. Significance was set at p < 0.05.Results
Comparison of the protective effects of PLCA and metformin
in NRVM after H/R stress
To determine whether PLCA exerted a protective effect
during the H/R condition, cell viability was assessed via
MTT assay. Metformin (30 μM) was used as an active
drug for comparison with PLCA. Cell viability declined
significantly after H/R stress. PLCA and metformin
both improved cell viability in NRVM after H/R stress
(Figure 2). PLCA exerted a protective effect that was
concentration dependent, ranging from 0.1 to 3 μM.
The protective effect of metformin (30 μM) was no
greater than that of PLCA (3 μM) in the H/R condition.Comparison of the protein expression between PLCA and
metformin in NRVM after H/R stress
To investigate the mechanisms of the protective effects
of PLCA and metformin in NRVM during in the H/R
condition, we evaluated the expression of several pro-
teins. PLCA and metformin both induced phosphoryl-
ation of AMPK (Figure 3A,B) and AKT (Figure 3A,C) in
NRVM after H/R stress, along with the elevation of
GLUT4 expression (Figure 3A,D). PLCA increased p-
AKT, p-AMPK, and GLUT4 expression with concentra-
tion dependence, ranging from 0.1 to 1 μM, but did not
show further increases of protein expression at 3 μM,
indicating a ceiling effect of PLCA at 1 μM. In addition,
no significant differences between PLCA (1 μM) and
metformin (30 μM) treatment were found in the expres-
sion of p-AKT, p-AMPK, and GLUT4 in NRVM after
H/R stress.
Figure 3 Effect of PLCA and metformin on protein expression in NRVM after H/R stress. Protein expression was measured in NRVM after
H/R stress. (A) Original western blots were shown. Ratios of (B) p-AMPK to actin, (C) p-AKT to actin, and (D) GLUT4 to actin. (n = 8) #P < 0.05 vs.
H/R + vehicle. Met = metformin.
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after H/R stress
We examined the effect of PLCA (1 μM) and metformin
(30 μM) on the progression of cell death in NRVM
after H/R stress using Annexin V-FITC and PI staining.
Cells shown in green were in an early stage of apop-
tosis (Figure 4A,B), and those in orange were in a late
stage of cell death (Figure 4A,C). It was observed that
both PLCA and metformin significantly decreased the
numbers of green and orange labeled cells, indicating
the alleviation of the progression of cell death in
NRVM in the H/R condition. The efficacies of PLCA
(1 μM) and metformin (30 μM) were exactly the same.
The subsequent experiments only investigate the effect
of PLCA (1 μM) in NRVM during H/R condition.
PLCA exerted a protective effect through the AMPK and
AKT pathway in NRVM after H/R stress
Since PLCA induced AMPK and AKT phosphorylation
in NRVM in the H/R condition, compound C and
LY294002 were used to block the AMPK and AKT path-
ways, respectively, in order to confirm the contributions
of AMPK and AKT signaling to the protective effects.
Compound C or LY294002 alone did not affect the cell
viability in the normoxia condition, but cell viability was
decreased in the H/R condition (Figure 5), indicating
that AMPK and AKT play important roles during H/R.
When PLCA combined with compound C or LY294002,PLCA lost its protective effect on cell viability in NRVM
after H/R stress.
We then investigated the protein expression of PLCA
treatment combined with compound C or LY294002. The
elevation of p-AMPK and p-AKT expression by PLCA in
NRVM in the H/R condition was completely abrogated
by its inhibitor, compound C or LY29400, respectively
(Figure 6A,B,C). Interestingly, LY29400 decreased the en-
hanced expression of p-AMPK in PLCA- treated NRVMs,
while compound C also diminished the enhanced expres-
sion of p-AKT expression in PLCA- treated NRVMs, indi-
cating cross-talk between AKT and AMPK signaling. In
addition, the elevation of GLUT4 expression by PLCA
in NRVMs during H/R condition was completely abol-
ished by compound C and LY29400 (Figure 6A,D). Active
caspase-3 expression was reduced by PLCA in NRVM
after H/R stress, and the protective effect was abrogated
by compound C and LY29400 (Figure 6A,E).
PLCA alleviated injury in rats subjected to myocardial I/R
The risk size was similar among groups (Figure 7A and
B), indicating that the procedure and severity of coron-
ary artery occlusion did not differ significantly among
groups. Rats subjected to coronary artery occlusion for
1 h followed by reperfusion for 2 h developed myocar-
dial infarction (Figure 7A and C). The protective effects
of caffeic acid and PLCA were compared. PLCA was
shown to attenuate infarct size more than caffeic acid
Figure 4 Effect of PLCA and metformin on cell death in NRVM
after H/R stress. Progression of cell death was measured in NRVM
after H/R stress. (A) Original microscopy photos were reported. Cells
indicated green are in early apoptosis (Annexin V-FITC positive
and PI negative). Cells indicated orange are in late apoptosis or
already dead (annexin V-FITC positive and PI positive). (B) Ratio
of early apoptosis cell. (C) Ratio of late apoptosis cell. (n = 5)
#P < 0.05 vs. H/R + vehicle.
Figure 5 Effect of the combined treatment of PLCA with
compound c or LY294002 on cell viability in NRVM after H/R
stress. Cell viability was measured after NRVM subjected to 6 h
hypoxia, and followed by 12 h reoxygenation. Compound C (15 μM)
or LY294002 (15 μM) were combined with PLCA (1 μM) before
hypoxia initiated. (n = 8) *P < 0.05 vs. control, #P < 0.05 vs. H/R +
vehicle, @P < 0.05 vs. H/R + PLCA. Met = metformin; LY = LY294002;
CC = compound C.
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respectively, at 1 mg/kg. The elevation of cardiac lactate
concentration after I/R injury was ameliorated by PLCA
(Figure 7D).
PLCA improved p-AMPK, p-AKT, and GLUT4 expression in
rats subjected to myocardial I/R
I/R resulted in 2.03-fold elevation of p-AMPK expression,
along with 1.06-fold elevation of GLUT4 expression
(Figure 8), but did not affect p-AKT expression. Treatment
with PLCA during I/R induced further prominentelevation of p-AMPK, GLUT4, and p-AKT expression,
being 1.53-, 2.62-, and 1.32- folds of I/R, respectively.
Discussion and conclusions
We demonstrated that both PLCA and metformin im-
proved cell viability and alleviated cell death in NRVM
after H/R stress. The protective effect is associated with
the elevation of AMPK and AKT phosphorylation, and
consequent regulation of downstream proteins, including
the induction of GLUT4 expression and the suppression
of caspase-3 expression. Treatment with PLCA (1 μM)
and metformin (30 μM) induced the same response in
regulation of and preservation of NRVM viability in the
H/R condition, suggesting that PLCA is more potent than
metformin in protecting against H/R injury. In the animal
study, PLCA demonstrated higher efficiency in protection
against myocardial I/R injury than its original compound,
caffeic acid. PLCA is a new potential drug for the treat-
ment of myocardial infarction.
Fatty acids generate more ATP per molecule of substrate
than glucose; therefore, the heart predominantly uses fatty
acids as fuel in the normal condition [28]. When oxygen
supply limits, glucose provides more energy per amount
of oxygen than fatty acids [29]. A shift in the myocardial
metabolism from fatty acid to glucose during myocardial
I/R is more oxygen efficient and prevents deleterious
effects [28]. Glucose enters cardiac myocytes via glucose
transporters, which is an important determinant for glyco-
lytic flux in cardiomyocyte [30]. GLUT4, the most abun-
dant transporter, translocates to the plasma membrane in
Figure 6 Effect of the combined treatment of PLCA with compound c or LY294002 on protein expression in NRVM after H/R stress.
Protein expression was measured in NRVM after H/R stress. (A) Original western blots were shown. Ratios of (B) p-AMPK to actin, (C) p-AKT to
actin, (D) GLUT4 to actin, and (E) caspase-3 to actin. (n = 8) #P < 0.05 vs. H/R+ vehicle, @ < 0.05 vs. H/R + PLCA. Met =metformin; LY = LY294002;
CC = compound C.
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for heart during H/R, while cardiac selective ablation
of GLUT4 directly influence cardiac function [32]. In
addition, ischemic preconditioning significantly im-
proved cardiac GLUT4 expression in heart, and GLUT4
siRNA blocks the cardioprotective effect on ischemic
preconditioning [32,33]. Activation of both AMPK and
AKT is involved in glycolysis improvement during heart
ischemia [9]. Augmentation of glycolysis becomes a
major mechanism for the heart to maintain ATPconcentrations in response to the impairment of oxida-
tive phosphorylation [29].
During myocardial reperfusion, fatty acid oxidation
quickly recovers and becomes the major source of energy
[34]. The high rate of fatty acid oxidation inhibits glucose
oxidation through Randle cycle mechanisms [20], result-
ing in a significant uncoupling between glycolysis and
glucose oxidation [34,35]. The uncoupling of glucose me-
tabolism produce lactate, which is a potential source of H+
production during reperfusion [2]. Stimulation of fatty
Figure 7 Effect of PLCA on myocardial I/R induced injury. Cardiac injury was shown after rats subjected to 1 h coronary artery occlusion and
followed by 2 h reperfusion. (A) Representative cardiac slices after I/R were shown. (B) Risk size and (C) infarct size were reported. The non-ischemic
myocardium stained blue, and the remnants indicated ischemic myocardium. The infarct myocardium stained white, and the non-infarct myocardium
stained red. Ratio of red plus white zone to total zone was defined as risk size. Ratio of white zone to red plus white zone was defined as infarct size.
(D) Cardiac lactate level was measured. (n = 6) *P < 0.05 vs. control, #P < 0.05 vs. I/R, @ < 0.05 vs. I/R + CA. CA = caffeic acid.
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glycolysis and glucose oxidation [36]. AMPK activation
accompanied by AKT activation may facilitate glucose
utilization and decrease the uncoupling of glycolysis and
glucose oxidation, which decrease lactate accumulation.
Our study demonstrated that PLCA activates both AMPK
and AKT to modulate the metabolic pathways in a heart
undergoing ischemia/reperfusion. Synergistic activation of
AMPK and AKT has been shown to regulate glucose me-
tabolism [37], implying the existence of cross-talk between
AMPK and AKT as we found here. We demonstrated that
the activations of AKT and AMPK are co-related, since
inhibiting one of the activities affects the phosphoryl-
ation state of the other. AMPK may regulate AKT
phosphorylation [33,38,39], and mTORC2 may be a me-
diator for AMPK to activate AKT [40]. Inhibition of
mTORC1 by AMPK could increase the availability of
mTOR to the mTORC2 complex, while mTORC2 directly
phosphorylates Akt at Ser473 [38,41]. The cross-talk
between AMPK and AKT is complicated. AKT has also
been shown to regulate AMPK phosphorylation, since
wortmannin, a PI3k inhibitor, blocks AKT and AMPK
phosphorylation as well as GLUT4 translocation and
subsequent ATP synthesis in ischemic preconditioning
[33]. The present study demonstrates that PLCA inducesAMPK and AKT in a cooperative manner to benefit the
heart by increasing glucose utilization during H/R stress.
Inhibition of apoptosis could decrease the infarct size
after I/R [42]. The reperfusion injury salvage kinase path-
way against cell apoptosis is through PI3K-AKTcascades
[15]. AKT is as a key regulator of metabolism and cell
survival [15]. Inhibition of AKT signaling by an inhibitor
or genetic deletion abrogates the protective effect, while
overexpression of AKT protects cardiomyocytes from
apoptosis induced by H/R [43]. Activation of AKT inhibits
pro-apoptotic proteins, such as bax, bad, bim, and p53,
and consequently inhibits caspase activation, finally
exerting a protective effect against myocardial I/R injury
[15]. In addition, AMPK activation is also reported to
have anti-apoptotic effects via increasing bcl2 expres-
sion and decreasing caspase-3 activity, whereas abrogation
of AMPK activation results in increasing apoptosis in
cardiomyocytes [44,45]. The inhibition of the cell death
pathway contributes to the protective action of PLCA
during I/R induced cell death.
In conclusion, the present study has identified the
cardioprotective mechanisms of PLCA. PLCA improves
cell viability in NRVM against H/R injury and decrease
myocardial infarction in rat against I/R injury by acti-
vating AKT- and AMPK-GLUT4 signaling, improving
Figure 8 Effect of PLCA on protein expression in heart after I/R stress. Protein expression was measured in heart after I/R stress. (A) Original
western blots were shown. Ratios of (B) p-AMPK to actin, (C) p-AKT to actin, and (D) GLUT4 to actin. (n = 4) *P < 0.05 vs. control, #P < 0.05 vs. I/R.
Figure 9 The mechanisms of PLCA in heart.
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(Figure 9). We provide a new insight into this potential
drug for the treatment of myocardial I/R injury.
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